1
|
Ramtohul T, Djerroudi L, Lissavalid E, Nhy C, Redon L, Ikni L, Djelouah M, Journo G, Menet E, Cabel L, Malhaire C, Tardivon A. Multiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive Breast Cancers. Radiology 2023; 308:e222646. [PMID: 37526540 DOI: 10.1148/radiol.222646] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/02/2023]
Abstract
Background Half of breast cancers exhibit low expression levels of human epidermal growth factor receptor 2 (HER2) and can be targeted by new antibody-drug conjugates. The imaging differences between HER2-zero (immunohistochemistry [IHC] score of 0), HER2-low (IHC score of 1+ or 2+ with negative findings at fluorescence in situ hybridization [FISH]), and HER2-positive (IHC score of 2+ with positive findings at FISH or IHC score of 3+) breast cancers were unknown. Purpose To assess whether multiparametric dynamic contrast-enhanced MRI-based radiomic features can help distinguish HER2 expressions in breast cancer. Materials and Methods This study included women with breast cancer who underwent MRI at two different centers between December 2020 and December 2022. Tumor segmentation and radiomic feature extraction were performed on T2-weighted and dynamic contrast-enhanced T1-weighted images. Unsupervised correlation analysis of reproducible features and least absolute shrinkage and selector operation were used for the selection of features to build a radiomics signature. The area under the receiver operating characteristic curve (AUC) was used to assess the performance of the radiomic signature. Multivariable logistic regression was used to identify independent predictors for distinguishing HER2 expressions in both the training and prospectively acquired external data set. Results The training set included 208 patients from center 1 (mean age, 53 years ± 14 [SD]), and the external test set included 131 patients from center 2 (mean age, 54 years ± 13). In the external test data set, the radiomic signature achieved an AUC of 0.80 (95% CI: 0.71, 0.89) for distinguishing HER2-low and -positive tumors versus HER2-zero tumors and was a significant predictive factor for distinguishing these two groups (odds ratio = 7.6; 95% CI: 2.9, 19.8; P < .001). Among HER2-low or -positive breast cancers, histology type, associated nonmass enhancement, and multiple lesions at MRI had an AUC of 0.77 (95% CI: 0.68, 0.86) in the external test set for the prediction of HER2-positive versus HER2-low cancers. Conclusion The radiomic signature and tumor descriptors from multiparametric breast MRI may predict distinct HER2 expressions of breast cancers with therapeutic implications. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Kataoka and Honda in this issue.
Collapse
Affiliation(s)
- Toulsie Ramtohul
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Lounes Djerroudi
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Emilie Lissavalid
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Caroline Nhy
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Louis Redon
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Laura Ikni
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Manel Djelouah
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Gabrielle Journo
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Emmanuelle Menet
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Luc Cabel
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Caroline Malhaire
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Anne Tardivon
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| |
Collapse
|
2
|
Hequet D, Hajjaji N, Charafe‐Jauffret E, Boucrauta A, Dalenc F, Nicolai V, Lopez J, Tredan O, Deluche E, Fermeaux V, Tixier L, Cayre A, Menet E, Lerebours F, Rouzier R. Compliance to genomic test recommendations to guide adjuvant chemotherapy decision-making in the case of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, in real-life settings. Cancer Med 2023; 12:16889-16895. [PMID: 37409516 PMCID: PMC10501273 DOI: 10.1002/cam4.6315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 03/06/2023] [Accepted: 06/23/2023] [Indexed: 07/07/2023] Open
Abstract
BACKGROUND Genomic tests are a useful tool for adjuvant chemotherapy decision-making in the case of hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) breast cancer with intermediate prognostic factors. Real-life data on the use of tests can help identify the target population for testing. METHODS French multicentric study (8 centers) including patients, all candidates for adjuvant chemotherapy for HR-positive, HER2-negative early breast cancer. We describe the percentage of tests performed outside recommendations, according to the year of testing. We calculated a ratio defined as the number of tests required to avoid chemotherapy for one patient, and according to patient and cancer characteristics. We then performed a cost-saving analysis using medical cost data over a period of 1 year from diagnosis, calculated from a previous study. Finally, we calculated the threshold of the ratio (number of tests required to avoid chemotherapy for one patient) below which the use of genomic tests was cost-saving. RESULTS A total of 2331 patients underwent a Prosigna test. The ratio (performed test/avoided chemotherapy) was 2.8 [95% CI: 2.7-2.9] in the whole population. In the group following recommendations for test indication, the ratio was 2.3 [95% CI: 2.2-2.4]. In the case of non-abidance by recommendations, the ratio was 3 [95% CI: 2.8-3.2]. Chemotherapy was avoided in 841 patients (36%) following the results of the Prosigna test. The direct medical costs saved over 1 year of care were 3,878,798€ and 1,718,472€ in the group of patients following test recommendations. We calculated that the ratio (performed test/avoided chemotherapy) needed to be under 6.9 for testing to prove cost-saving. CONCLUSION The use of genomic testing proved cost-saving in this large multicentric real-life analysis, even in certain cases when the test was performed outside recommendations.
Collapse
Affiliation(s)
- D. Hequet
- Surgery DepartmentInstitut CurieSt. CloudFrance
- PSLSt. CloudU900INSERMFrance
| | - N. Hajjaji
- Breast Cancer DepartmentOscar Lambret Cancer CenterLilleFrance
- Laboratoire Protéomique, Réponse inflammatoire et Spectométrie de Masse (PRISM)University of LilleLilleU1192InsermFrance
| | | | - A. Boucrauta
- Department of BiopathologyInstitut Paoli CalmettesMarseilleFrance
| | - F. Dalenc
- Department of Medical OncologyInstitut universitaire du cancer‐oncopole, Institut Claudius‐RegaudToulouseFrance
| | - V. Nicolai
- Department of Medical OncologyInstitut universitaire du cancer‐oncopole, Institut Claudius‐RegaudToulouseFrance
| | - J. Lopez
- Department of BiopathologyHospices Civiles de LyonLyonFrance
| | - O. Tredan
- Department of Medical OncologyCentre Leon BerardLyonFrance
- Centre de Recherche en Cancerologie de LyonLyonUMR5286CNRSFrance
| | - E. Deluche
- Department of Medical OncologyCHULimogesFrance
| | | | - L. Tixier
- Department of BiopathologyCenter Jean PerrinClermont FerrandFrance
- University Clermont AuvergneClermont‐FerrandU1240INSERMFrance
| | - A. Cayre
- Department of BiopathologyCenter Jean PerrinClermont FerrandFrance
- University Clermont AuvergneClermont‐FerrandU1240INSERMFrance
| | - E. Menet
- Pathology DepartmentInstitut CurieSt. CloudFrance
| | - F. Lerebours
- Oncology DepartmentInstitut CurieSt. CloudFrance
| | - R. Rouzier
- Surgery DepartmentCentre François BaclesseCaenFrance
| |
Collapse
|
3
|
Hequet D, Rouzier R, Lerebours F, Menet E, Dalenc F, Nicolai V, Hajjaji N, Lavau-Denes S, Fermeaux V, Texier L, Cayre A, Jauffret EC, Boucrauta A, Tredan O, Lopez J. 175P Prosigna test for early breast cancer patients in real-life. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
4
|
Hequet D, Harrissart G, Krief D, Maumy L, Lerebours F, Menet E, Callens C, Rouzier R. Prosigna test in breast cancer: real-life experience. Breast Cancer Res Treat 2021; 188:141-147. [PMID: 33860387 DOI: 10.1007/s10549-021-06191-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Accepted: 03/10/2021] [Indexed: 12/16/2022]
Abstract
PURPOSE Genomic tests can guide the decision to administer adjuvant chemotherapy in women with hormone receptor (HR)-positive, Human Epidermal growth Factor 2 (HER2)-negative breast cancer (BC) at intermediate risk of recurrence. We assessed the decision-making and economic impact of the Prosigna test in a real-life setting. METHODS Retrospective cohort study of HR + , HER2- BC patients managed from 2016 to 2020, potential candidates for adjuvant chemotherapy, at intermediate risk of recurrence, in whom a Prosigna test was performed according to contemporary guidelines. The additional cost of chemotherapy over one year in terms of direct medical and non-medical costs was estimated in this study to be €9,737 (derived from a previous study, NCT02813317). The cost of the Prosigna test, as defined by the reimbursement system, was €1,849. RESULTS Among the 809 patients included in this study, 2.3 Prosigna tests had to be performed to avoid adjuvant chemotherapy for one patient. The number of tests that had to be performed to avoid chemotherapy for one patient was higher for patients with grade 3 tumors and pN1mic axillary node involvement and lower for grade 1 tumors or in the absence of axillary node involvement (pN0), but did not vary according to the 10-year overall survival gain predicted by the Predict online test. The cost saving related to withholding of adjuvant chemotherapy for one patient on the basis of the Prosigna test results was €5,485. CONCLUSION We present one of the largest cohorts of HR + , HER2- BC patients at intermediate risk of recurrence, in whom a Prosigna test was used to guide the adjuvant therapy decision in a real-life setting, resulting in a 44% decrease in the indication for chemotherapy.
Collapse
Affiliation(s)
- D Hequet
- Department of Surgical Oncology, Institut Curie, St Cloud, France.
- INSERM U900, Institut Curie, St Cloud, France.
| | - G Harrissart
- Department of Surgical Oncology, Institut Curie, St Cloud, France
| | - D Krief
- Department of Surgical Oncology, Institut Curie, St Cloud, France
| | - L Maumy
- Department of Surgical Oncology, Institut Curie, St Cloud, France
| | - F Lerebours
- Department of Medical Oncology, Institut Curie, St Cloud, France
| | - E Menet
- Department of Pathology, Institut Curie, St Cloud, France
| | - C Callens
- Pharmacogenomics Unit, Department of Genetics, Institut Curie, Paris, France
| | - R Rouzier
- Department of Surgical Oncology, Institut Curie, St Cloud, France
- INSERM U900, Institut Curie, St Cloud, France
| |
Collapse
|
5
|
Hamy AS, Bonsang-Kitzis H, De Croze D, Laas E, Darrigues L, Topciu L, Menet E, Vincent-Salomon A, Lerebours F, Pierga JY, Brain E, Feron JG, Benchimol G, Lam GT, Laé M, Reyal F. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Clin Cancer Res 2019; 25:6731-6741. [PMID: 31515462 DOI: 10.1158/1078-0432.ccr-18-3017] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2018] [Revised: 02/12/2019] [Accepted: 08/30/2019] [Indexed: 11/16/2022]
Abstract
PURPOSE High levels of tumor-infiltrating lymphocytes (TIL) before neoadjuvant chemotherapy (NAC) are associated with higher pathologic complete response (pCR) rates and better survival in triple-negative breast cancer (TNBC) and HER2-positive breast cancer. We investigated the value of TIL levels by evaluating lymphocyte infiltration before and after NAC. EXPERIMENTAL DESIGN We assessed stromal TIL levels in 716 pre- and posttreatment matched paired specimens, according to the guidelines of the International TIL Working Group. RESULTS Pre-NAC TIL levels were higher in tumors for which pCR was achieved than in cases with residual disease (33.9% vs. 20.3%, P = 0.001). This was observed in luminal tumors and TNBCs, but not in HER2-positive breast cancers (P Interaction = 0.001). The association between pre-NAC TIL levels and pCR was nonlinear in TNBCs (P = 0.005). Mean TIL levels decreased after chemotherapy completion (pre-NAC TILs: 24.1% vs. post-NAC TILs: 13.0%, P < 0.001). This decrease was strongly associated with high pCR rates, and the variation of TIL levels was strongly inversely correlated with pre-NAC TIL levels (r = -0.80, P < 0.001). Pre-NAC TILs and disease-free survival (DFS) were associated in a nonlinear manner (P < 0.001). High post-NAC TIL levels were associated with aggressive tumor characteristics and with impaired DFS in HER2-positive breast cancers (HR, 1.04; confidence interval, 1.02-1.06; P = 0.001), but not in luminal tumors or TNBCs (P Interaction = 0.04). CONCLUSIONS The associations of pre- and post-NAC TIL levels with response to treatment and DFS differ between breast cancer subtypes. The characterization of immune subpopulations may improve our understanding of the complex interactions between pre- or post-NAC setting, breast cancer subtype, response to treatment, and prognosis.
Collapse
Affiliation(s)
- Anne-Sophie Hamy
- Residual Tumor and Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France.,Department of Medical Oncology, Institut Curie, Paris, France
| | - Hélène Bonsang-Kitzis
- Residual Tumor and Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France.,Department of Surgery, Institut Curie, Paris, France
| | - Diane De Croze
- Department of Tumor Biology, Hôpital René Huguenin, Saint-Cloud, France
| | - Enora Laas
- Department of Surgery, Institut Curie, Paris, France
| | | | - Lucian Topciu
- Department of Tumor Biology, Institut Curie, Paris, France
| | - Emmanuelle Menet
- Department of Tumor Biology, Hôpital René Huguenin, Saint-Cloud, France
| | | | - Florence Lerebours
- Department of Medical Oncology, Hôpital René Huguenin, Saint-Cloud, France
| | - Jean-Yves Pierga
- Department of Medical Oncology, Institut Curie, Paris, France.,Université Paris, Paris, France
| | - Etienne Brain
- Department of Medical Oncology, Hôpital René Huguenin, Saint-Cloud, France
| | | | | | - Giang-Thanh Lam
- Department of Surgery, Institut Curie, Paris, France.,Department of Gynecology and Obstetrics, Geneva University Hospitals, Geneva, Switzerland
| | - Marick Laé
- Department of Tumor Biology, Institut Curie, Paris, France
| | - Fabien Reyal
- Residual Tumor and Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France. .,Department of Surgery, Institut Curie, Paris, France.,Université Paris, Paris, France
| |
Collapse
|
6
|
Hamy AS, Bonsang-Kitzis H, De Croze D, Laas E, Darrigues L, Topciu L, Menet E, Vincent-Salomon A, Lerebours F, Pierga JY, Brain E, Feron JG, Benchimol G, Lam GT, Laé M, Reyal F. Abstract P3-11-01: Interaction between molecular subtype and stromal immune infiltration dynamics in breast cancer patients treated with neoadjuvant chemotherapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-11-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: High levels of tumor-infiltrating lymphocytes (TILs) before neoadjuvant chemotherapy (NAC) are associated with higher pathological complete response (pCR) rates, and better survival in TNBC and HER2-positive breast cancers (BCs). We investigated the value of changes in TIL levels and final TIL levels after treatment, by evaluating lymphocyte infiltration before and after NAC in a real-life BC cohort.
Patients and methods: We assessed stromal TIL levels in 716 pre- and post-treatment matched paired specimens, according to the guidelines of the international TIL working group.
Results: Pre-NAC TIL levels were higher in tumors for which pCR was achieved than in cases of residual disease (33.9% versus 20.3%, p=0.001), in luminal tumors and TNBCs, but not in HER2-positive BCs, (pInteraction =0.001). The association between pre-NAC TIL levels and pCR was non-linear in TNBCs (p=0.005). Mean TIL levels decreased during NAC (pre-NAC TILs: 24.1% versus post-NAC TILs: 13.0%, p<0.001). This decrease was strongly associated with high pCR rates, and TIL level variation was strongly inversely correlated with pre-NAC TIL levels (r=-0.80, p<0.001). Pre-NAC TILs and disease-free survival (DFS) were associated in a non-linear manner (p<0.001). High post-NAC TIL levels were associated with aggressive tumor characteristics and with impaired DFS in HER2-positive BCs (HR=1.04, CI [1.02-1.06], p=0.001), but not in luminal tumors or TNBCs (pInteraction =0.04).
Conclusion: The associations of pre, post-NAC TIL levels with response to treatment and DFS differ between BC subtypes and may deviate from linearity. The characterization of immune subpopulations may improve our understanding of the complex interactions between pre- or post-NAC setting, BC subtype, response to treatment and prognosis.
Citation Format: Hamy A-S, Bonsang-Kitzis H, De Croze D, Laas E, Darrigues L, Topciu L, Menet E, Vincent-Salomon A, Lerebours F, Pierga J-Y, Brain E, Feron J-G, Benchimol G, Lam G-T, Laé M, Reyal F. Interaction between molecular subtype and stromal immune infiltration dynamics in breast cancer patients treated with neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-11-01.
Collapse
Affiliation(s)
- A-S Hamy
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - H Bonsang-Kitzis
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - D De Croze
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - E Laas
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - L Darrigues
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - L Topciu
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - E Menet
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - A Vincent-Salomon
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - F Lerebours
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - J-Y Pierga
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - E Brain
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - J-G Feron
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - G Benchimol
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - G-T Lam
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - M Laé
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| | - F Reyal
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; PSL Research University, Institut Curie, Paris, France; Hôpital René Huguenin, Saint-Cloud, France; Université Paris Descartes, Paris, France; Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
7
|
Pouzoulet F, Alentorn A, Royer-Perron L, Assayag F, Mokhtari K, Labiod D, Le Garff-Tavernier M, Daniau M, Menet E, Peyre M, Schnitzler A, Guegan J, Davi F, Hoang-Xuan K, Soussain C. Primary CNS lymphoma patient-derived orthotopic xenograft model capture the biological and molecular characteristics of the disease. Blood Cells Mol Dis 2018; 75:1-10. [PMID: 30502564 DOI: 10.1016/j.bcmd.2018.11.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2018] [Accepted: 11/15/2018] [Indexed: 12/14/2022]
Abstract
Primary CNS lymphomas (PCNSL) are rare and poor prognosis diffuse large B-cell lymphomas. Because of the brain tumor environment and the restricted distribution of drugs in the CNS, specific PCNSL patient-derived orthotopic xenograft (PDOX) models are needed for preclinical research to improve the prognosis of PCNSL patients. PCNSL patient specimens (n = 6) were grafted in the caudate nucleus of immunodeficient nude mice with a 83% rate of success, while subcutaneous implantation in nude mice of human PCNSL sample did not generate lymphoma, supporting the role of the brain microenvironment in the PCNSL physiopathology. PDOXs showed diffuse infiltration of B-cell lymphoma cells in the brain parenchyma. Each model had a unique mutational signature for genes in the BCR and NF-κB pathways and retained the mutational profile of the primary tumor. The models can be stored as cryopreserved biobank. Human IL-10 levels measured in the plasma of PCNSL-PDOX mice showed to be a reliable tool to monitor the tumor burden. Treatment response could be measured after a short treatment with the targeted therapy ibrutinib. In summary, we established a panel of human PCNSL-PDOX models that capture the histological and molecular characteristics of the disease and that proved suitable for preclinical experiments. Our methods of generation and characterization will enable the generation of additional PDOX-PCNSL models, essential tools for cognitive and preclinical drug discovery.
Collapse
Affiliation(s)
- Frédéric Pouzoulet
- Experimental Radiotherapy Platform, Translationnal Research Department, Institut Curie, Orsay, France
| | - Agusti Alentorn
- Groupe Hospitalier Pitié-Salpétrière, Neuro-oncology, Paris, France; Paris University Sorbonne UPMC, INSERM U1127, CNRS UMR 7225, IHU, ICM, France
| | - Louis Royer-Perron
- Paris University Sorbonne UPMC, INSERM U1127, CNRS UMR 7225, IHU, ICM, France
| | - Franck Assayag
- Experimental Radiotherapy Platform, Translationnal Research Department, Institut Curie, Orsay, France
| | - Karima Mokhtari
- Groupe Hospitalier Pitié-Salpétrière, Neuro-Pathology, Paris, France
| | - Dalila Labiod
- Experimental Radiotherapy Platform, Translationnal Research Department, Institut Curie, Orsay, France
| | - Magali Le Garff-Tavernier
- Groupe Hospitalier Pitié-Salpétrière, Biological Hematology, Paris, France; Paris University Sorbonne UPMC, INSERM UMRS 1138, Paris, France
| | - Mailys Daniau
- Paris University Sorbonne UPMC, INSERM U1127, CNRS UMR 7225, IHU, ICM, France
| | | | - Matthieu Peyre
- Groupe Hospitalier Pitié-Salpétrière, Neurosurgery, Paris, France
| | - Anne Schnitzler
- Institut Curie, Site Paris, Pharmacogenomics Unit, Genetics Department, Paris, France
| | - Justine Guegan
- Paris University Sorbonne UPMC, INSERM U1127, CNRS UMR 7225, IHU, ICM, France
| | - Frédéric Davi
- Groupe Hospitalier Pitié-Salpétrière, Biological Hematology, Paris, France
| | - Khê Hoang-Xuan
- Groupe Hospitalier Pitié-Salpétrière, Neuro-oncology, Paris, France
| | - Carole Soussain
- Institut Curie, Site Saint-Cloud Hematology, Saint-Cloud, France.
| |
Collapse
|
8
|
Alberini JL, Boisgard R, Guillermet S, Siquier K, Jego B, Thézé B, Urien S, Rezaï K, Menet E, Maroy R, Dollé F, Kühnast B, Tavitian B. Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer. Mol Imaging Biol 2017; 18:617-26. [PMID: 26630973 PMCID: PMC4927598 DOI: 10.1007/s11307-015-0916-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Purpose Transgenic mice expressing the polyoma middle T oncoprotein (PyMT) in the mammary epithelium were explored by multimodal imaging to monitor longitudinally spontaneous tumor growth and response to chemotherapy. Procedures Positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) and 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT), single photon emission tomography (SPECT) with [99mTc]TcO4 ([99mTc]TEC), X-ray computed tomography, and fluorescent confocal endomicroscopy (FCE) images were acquired during tumor progression in female PyMT mice. Imaging with [18F]FDG and [99mTc]TEC was also performed in untreated, doxorubicin-treated, and docetaxel-treated PyMT mice. Total tumor volumes were quantified. Tumors were collected and macroscopic and histological examinations were performed. Results All PyMT mice developed multifocal tumors of the mammary epithelium that became palpable at 8 weeks of age (W8). Computed tomography (CT) detected tumors at W14, while a clear tumoral uptake of [99mTc]TEC and [18F]FDG was present as early as W6 and W8, respectively. No contrast between mammary tumors and surrounding tissue was observed at any stage with [18F]FLT. FCE detected an angiogenic switch at W10. Lung metastases were not clearly evidenced by imaging. Doxorubicin and docetaxel treatments delayed tumor growth, as shown by [18F]FDG and [99mTc]TEC, but tumor growth resumed upon treatment discontinuation. Tumor growth fitted an exponential model with time constant rates of 0.315, 0.145, and 0.212 week−1 in untreated, doxorubicin, and docetaxel groups, respectively. Conclusions Molecular imaging of mammary tumors in PyMT is precocious, precise, and predictive. [18F]FDG-PET and [99mTc]TEC SPECT monitor tumor response to chemotherapy. Electronic supplementary material The online version of this article (doi:10.1007/s11307-015-0916-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Jean-Louis Alberini
- CEA, DSV, I2BM, Service Hospitalier Frédéric Joliot, Laboratoire d'Imagerie Moléculaire Expérimentale, Orsay, France.,Service de Médecine nucléaire, Institut Curie, Hôpital René Huguenin, Saint-Cloud, France.,Faculté de Médecine, Université Versailles Saint-Quentin, Versailles, France
| | - Raphaël Boisgard
- CEA, DSV, I2BM, Service Hospitalier Frédéric Joliot, Laboratoire d'Imagerie Moléculaire Expérimentale, Orsay, France
| | - Stéphanie Guillermet
- CEA, DSV, I2BM, Service Hospitalier Frédéric Joliot, Laboratoire d'Imagerie Moléculaire Expérimentale, Orsay, France
| | - Karine Siquier
- CEA, DSV, I2BM, Service Hospitalier Frédéric Joliot, Laboratoire d'Imagerie Moléculaire Expérimentale, Orsay, France
| | - Benoît Jego
- CEA, DSV, I2BM, Service Hospitalier Frédéric Joliot, Laboratoire d'Imagerie Moléculaire Expérimentale, Orsay, France
| | - Benoît Thézé
- CEA, DSV, I2BM, Service Hospitalier Frédéric Joliot, Laboratoire d'Imagerie Moléculaire Expérimentale, Orsay, France
| | - Saik Urien
- Service de pharmacologie, Institut Curie, Hôpital René Huguenin, Saint-Cloud, France
| | - Keyvan Rezaï
- Service de pharmacologie, Institut Curie, Hôpital René Huguenin, Saint-Cloud, France
| | - Emmanuelle Menet
- Service de pathologie, Institut Curie, Hôpital René Huguenin, Saint-Cloud, France
| | - Renaud Maroy
- CEA, DSV, I2BM, Service Hospitalier Frédéric Joliot, Laboratoire d'Imagerie Moléculaire Expérimentale, Orsay, France
| | - Frédéric Dollé
- CEA, DSV, I2BM, Service Hospitalier Frédéric Joliot, Laboratoire d'Imagerie Moléculaire Expérimentale, Orsay, France
| | - Bertrand Kühnast
- CEA, DSV, I2BM, Service Hospitalier Frédéric Joliot, Laboratoire d'Imagerie Moléculaire Expérimentale, Orsay, France
| | - Bertrand Tavitian
- Université Paris Descartes Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Radiology Department, Paris, France. .,Université Paris Descartes Sorbonne Paris Cité, INSERM UMR 970, Cardiovascular Research Center - PARCC, 56 rue Leblanc, 75015, Paris, France.
| |
Collapse
|
9
|
Berdelou A, Nascimento C, Menet E. [Discovery of a thyroid nodule]. Rev Prat 2017; 67:521-526. [PMID: 30512671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- Amandine Berdelou
- Service de médecine nucléaire, Curie, Saint-Cloud, France
- Service de médecine nucléaire et oncologie endocrinienne, institut Gustave-Roussy et université Paris-Saclay, Villejuif, France
| | | | - Emmanuelle Menet
- Service de médecine nucléaire et oncologie endocrinienne, institut Gustave-Roussy et université Paris-Saclay, Villejuif, France
| |
Collapse
|
10
|
Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, Traverse-Glehen A, Rousset T, Quintin-Roue I, Petrella T, Emile JF, Amara N, Rochaix P, Chenard-Neu MP, Tasei AM, Menet E, Chomarat H, Costes V, Andrac-Meyer L, Michiels JF, Chassagne-Clement C, de Leval L, Brousset P, Delsol G, Lamant L. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol 2015; 27:306-14. [PMID: 26598546 DOI: 10.1093/annonc/mdv575] [Citation(s) in RCA: 155] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Accepted: 11/11/2015] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND ALK-negative anaplastic large cell lymphoma associated with breast implant (i-ALCL) has been recently recognized as a distinct entity. Among 43 830 lymphomas registered in the French Lymphopath network since 2010, 300 breast lymphomas comprising 25 peripheral T-cell lymphomas (PTCL) were reviewed. Among PTCL, ALK-negative ALCL was the most frequent and all of them were associated with breast implants. PATIENTS AND METHODS Since 2010, all i-ALCL cases were collected from different institutions through Lymphopath. Immuno-morphologic features, molecular data and clinical outcome of 19 i-ALCLs have been retrospectively analyzed. RESULTS The median age of the patients was 61 years and the median length between breast implant and i-ALCL was 9 years. Most implants were silicone-filled and textured. Implant removal was performed in 17 out of 19 patients with additional treatment based on mostly CHOP or CHOP-like chemotherapy regimens (n = 10/19) or irradiation (n = 1/19). CHOP alone or ABVD following radiation without implant removal have been given in two patients. The two clinical presentations, i.e. effusion and less frequently tumor mass correlated with distinct histopathologic features: in situ i-ALCL (anaplastic cell proliferation confined to the fibrous capsule) and infiltrative i-ALCL (pleomorphic cells massively infiltrating adjacent tissue with eosinophils and sometimes Reed-Sternberg-like cells mimicking Hodgkin lymphoma). Malignant cells were CD30-positive, showed a variable staining for EMA and were ALK negative. Most cases had a cytotoxic T-cell immunophenotype with variable T-cell antigen loss and pSTAT3 nuclear expression. T-cell receptor genes were clonally rearranged in 13 out of 13 tested cases. After 18 months of median follow-up, the 2-year overall survival for in situ and infiltrative i-ALCL was 100% and 52.5%, respectively. CONCLUSIONS In situ i-ALCLs have an indolent clinical course and generally remain free of disease after implant removal. However, infiltrative i-ALCLs could have a more aggressive clinical course that might require additional therapy to implant removal.
Collapse
Affiliation(s)
- C Laurent
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse INSERM, U.1037, Centre de recherche en cancérologie de Toulouse-Purpan, Toulouse
| | - A Delas
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse
| | - P Gaulard
- Department of Pathology, AP-HP, Groupe hospitalier Henri Mondor-Albert Chenevier, Créteil INSERM U955, Université Paris-Est, Créteil
| | - C Haioun
- INSERM U955, Université Paris-Est, Créteil Lymphoid Malignancies Unit, AP-HP, Groupe hospitalier Henri Mondor-Albert Chenevier, Créteil
| | - A Moreau
- Department of Pathology, Centre Hospitalier Hôtel Dieu, Nantes
| | - L Xerri
- Department of Pathology, Institut Paoli-Calmettes, Marseille
| | | | - T Rousset
- Department of Pathology, Hôpital Gui de Chauliac-Saint Eloi, Montpellier
| | - I Quintin-Roue
- Department of Pathology, Centre Hospitalier de Brest, Brest, France
| | - T Petrella
- Département de Pathologie, Montréal, Canada
| | - J F Emile
- Department of Pathology, Hôpital Ambroise Paré, Boulogne
| | - N Amara
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse
| | - P Rochaix
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse
| | | | - A M Tasei
- Department of Pathology, Centre Hospitalier Henri Duffaut, Avignon
| | - E Menet
- Department of Pathology, Hôpital René Huguenin, Saint Cloud
| | | | - V Costes
- Department of Pathology, Hôpital Gui de Chauliac-Saint Eloi, Montpellier
| | | | - J F Michiels
- Department of Pathology, Centre Hospitalier Pasteur L'Archet, Nice
| | | | - L de Leval
- Pathology institut of Lausanne, Centre Hospitalier Universitaire Vaudois, Suisse, Lausanne, Switzerland
| | - P Brousset
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse INSERM, U.1037, Centre de recherche en cancérologie de Toulouse-Purpan, Toulouse
| | - G Delsol
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse INSERM, U.1037, Centre de recherche en cancérologie de Toulouse-Purpan, Toulouse
| | - L Lamant
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse INSERM, U.1037, Centre de recherche en cancérologie de Toulouse-Purpan, Toulouse
| |
Collapse
|
11
|
Bataillon G, Collet JF, Voillemot N, Menet E, Vincent-Salomon A, Klijanienko J. Fine-needle aspiration of low-grade adenosquamous carcinomas of the breast: a report of three new cases. Acta Cytol 2014; 58:427-31. [PMID: 25322776 DOI: 10.1159/000367585] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2014] [Accepted: 08/12/2014] [Indexed: 11/19/2022]
Abstract
OBJECTIVES To describe cytology patterns in low-grade adenosquamous carcinomas (LGASCs) of the breast. STUDY DESIGN Low-grade adenosquamous carcinomas of the breast are a recently described rare variant of primary metaplastic carcinomas characterized by clinical indolence, slow evolution and excellent survival. To date, only 7 cases of LGASC were studied cytologically, and it was demonstrated that LGASC identification was difficult because its cellular components exhibited unspecific and nonsuspicious features. They consisted of irregularly clustered cells without prominent cytonuclear atypia, mitosis or necrosis. The presence of metaplastic cells or keratin debris was helpful in accurate tumor typing. We report here 3 additional cases of LGASC that were initially studied by fine-needle aspiration. RESULTS We have also encountered diagnostic difficulties and misdiagnosed tumors, since 2 cases were underdiagnosed as 'suspicious' and only 1 was accurately diagnosed as malignancy. CONCLUSION The review of our cases and the literature confirms that, despite its putative metaplastic origin, LGASC is an entity which is difficult to diagnose using classical cytological methods. Moreover, core-needle biopsy as well as frozen sections may also misdiagnose LGASC as a benign breast lesion.
Collapse
|
12
|
Becette V, Lerebours F, Spyratos F, Menet E, Tubiana-Hulin M, Briffod M. Immunomarker studies of fine-needle cytopuncture cell blocks for tumor response prediction after preoperative chemotherapy and prognosis in operable nonmetastatic primary breast carcinoma. Breast J 2011; 17:121-8. [PMID: 21306468 DOI: 10.1111/j.1524-4741.2010.01040.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Neo-adjuvant chemotherapy of breast cancer provides an opportunity to evaluate predictive factors at initial tumor biopsy. We evaluated these factors on cell blocks obtained by diagnostic fine-needle cytopuncture (FNC), with respect to tumor regression and outcome. A prospective study (1996-2003, median follow-up 82 months) involved 163 patients with breast carcinoma (T2 ≥ 3 cm, T3, T4 noninflammatory) diagnosed by means of FNC. Malignancy, cytologic grade, and the presence of lymphocytes were determined on cytologic smears. Ki67, estrogen receptor (ER), progesterone receptor (PgR), HER2, and p53 expression was assessed on cell blocks by means of immunohistochemistry. All the patients received anthracycline-based chemotherapy. A combined clinical and pathologic tumor regression score was calculated. Twelve cases (7.5%) showed a complete regression, 72 cases (44%) a partial regression and 79 cases (48.5%) no regression. Factors predictive of regression were high grade, presence of lymphocytes, pN0, high Ki67 expression, hormone receptor negativity, and the "triple negative" phenotype. In univariate analysis 5-year metastasis-free survival rate (MFS) correlated with cytologic grade, pN, ER, and p53 status, while overall survival (OS) correlated with cytologic grade, type of surgery, pN, and ER status. In multivariate analysis, MFS was significantly influenced by the regression score, Ki67, age, ER status, pN, HER2, and initial tumor size. Except for age, the same parameters correlated with OS. FNC with the cell block technique is a rapid, minimally invasive, reliable, and inexpensive method for analyzing predictive biomarkers, and may thus be useful in the management of breast cancer patients requiring neo-adjuvant chemotherapy.
Collapse
Affiliation(s)
- Véronique Becette
- Departments of Pathology Medical Oncology Oncogenetics, Institut Curie - Hôpital René Huguenin, Saint-Cloud, France.
| | | | | | | | | | | |
Collapse
|
13
|
Guinebretière JM, Menet E, Suciu V, Cherel P. Comment analyser un compte rendu anatomopathologique de biopsie dirigée du sein ? Imagerie de la Femme 2010. [DOI: 10.1016/j.femme.2010.02.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
14
|
Suciu V, Menet E, Guinebretière JM, Trassard M, Vielh P. [Apocrine lesions in breast pathology]. Ann Pathol 2009; 29 Spec No 1:S112-3. [PMID: 19887237 DOI: 10.1016/j.annpat.2009.07.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2009] [Accepted: 07/22/2009] [Indexed: 11/17/2022]
Affiliation(s)
- Voichita Suciu
- Service de pathologie, centre René-Huguenin, rue Dailly, Saint-Cloud, France.
| | | | | | | | | |
Collapse
|
15
|
Menet E, Becette V, Briffod M. Cytologic diagnosis of lobular carcinoma of the breast: experience with 555 patients in the Rene Huguenin Cancer Center. Cancer 2008; 114:111-7. [PMID: 18300231 DOI: 10.1002/cncr.23347] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Fine-needle aspiration generally produces results that are not as good for lobular carcinoma as the results for ductal carcinoma of the breast. In this study, the authors evaluated their team's performance in cytologic diagnosis of lobular carcinoma over 11 years and analyzed the reasons for diagnostic failure. METHODS Cytologic findings were analyzed in 555 consecutive fine-needle cytopuncture specimens from women with palpable, invasive lobular carcinoma of the breast. The authors also examined the influence of the cytologist's experience, the clinical tumor size, the histologic subtype, and the histologic grade on diagnostic performance. All negative samples were re-examined, along with all samples that had been obtained during the last year of the study, to refine the morphologic description of lobular carcinoma. RESULTS Malignancy was diagnosed in 68.8% of specimens overall. The individual pathologists diagnosed malignancy in from 44.4% to 81.1% of specimens, depending on their experience. Diagnostic performance was correlated with clinical tumor size, histologic grade, and histologic subtype, and correct diagnoses were significantly more frequent in pleomorphic subtypes than in "classic" types. Re-examination of all 32 negative specimens reduced the false-negative rate from 5.8% to 3.8%. CONCLUSIONS Despite the pitfalls associated with lobular carcinoma of the breast, fine-needle cytopuncture remains a useful diagnostic tool before treatment. Failures can be reduced through experience and by better knowledge of cytologic features.
Collapse
Affiliation(s)
- Emmanuelle Menet
- Department of Pathology, René Huguenin Center, St. Cloud, France.
| | | | | |
Collapse
|
16
|
Guinebretière JM, Menet E, Fourme E, Chérel P, Bélichard C. Lésions frontières du sein. Imagerie de la Femme 2007. [DOI: 10.1016/s1776-9817(07)88740-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Guinebretiére JM, Menet E, Briffod M. Cytoponctions vs microbiopsies dans les tumeurs palpables. Pour qui, pour quoi? ONCOLOGIE 2006. [DOI: 10.1007/s10269-006-0375-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
18
|
Guinebretière JM, Menet E, Tardivon A, Cherel P, Vanel D. Normal and pathological breast, the histological basis. Eur J Radiol 2005; 54:6-14. [PMID: 15797289 DOI: 10.1016/j.ejrad.2004.11.020] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2004] [Revised: 11/26/2004] [Accepted: 11/29/2004] [Indexed: 10/25/2022]
Abstract
Breast tissue is heterogeneous, associating connective and glandular structures, which grow and change cyclically under hormonal regulation. Hormones are also thought to be the main determinant of the major benign and malignant pathologies encountered in the breast. Benign lesions are more frequent and fibrocystic changes are by far the most common among them. They usually associate different entities, (adenosis, fibrosis, cysts and hyperplasia) but vary in intensity and extension. Thus, their clinical and radiographic presentation is extremely different from one patient to another. Adenofibroma is the most frequent tumour. It also undergoes modifications according to hormonal conditions. About 90% of malignant tumours are primary carcinoma. The incidence of intra-ductal carcinoma has risen dramatically since the development of screening because of its ability to induce calcification. Two mechanisms could be involved in the formation of calcification: one active (tumour cell secretion of vesicles), the other passive (necrotic cell fragments are released). Invasive carcinoma comprises numerous histological types. Stromal reactions essentially determines their shape: a fibrous reaction commonly found in ductal carcinoma creates a stellate lesion while other stroma, inflammatory (medullary carcinoma), vascular (papillary carcinoma) or mucinous determine nodular lesions whose borders push the surrounding tissue. The histological features which give rise to the radiographic pattern will be emphasised.
Collapse
Affiliation(s)
- J M Guinebretière
- Department of Pathology, Centre René-Huguenin, 35 rue Dailly, 92210 Saint Cloud, France.
| | | | | | | | | |
Collapse
|
19
|
Becette V, Vignaud S, Régnier C, Labroquére M, Fourme E, Menet E, Bièche I, Spyratos F. Gene transcript assay by real-time RT-PCR in epithelial breast cancer cells selected by laser microdissection. Int J Biol Markers 2005; 19:100-8. [PMID: 15255541 DOI: 10.1177/172460080401900203] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The cell type heterogeneity within clinical cancer tissue samples may affect the accuracy of gene expression analysis. In order to validate our laser microdissection (LMD) method using the Leica AS LMD system (LEICA Microsystems), we compared the mRNA levels of three major genes involved in breast cancer (ERalpha, PR, HER2), measured by means of real-time quantitative RT-PCR, in 5000 microdissected malignant epithelial cells and in corresponding bulk tumor homogenates from 14 patients. We also compared the mRNA level results to protein expression measured by immunohistochemistry (IHC) on the same tumors. For the three genes, significant correlations were found between mRNA results obtained on microdissected cells and IHC. Comparison between IHC and mRNA results obtained on microdissected cells and bulk tumors showed that in all cases microdissection enhanced the sensitivity of assessing target gene transcript levels and was essential for their accurate evaluation in heterogeneous tumors.
Collapse
Affiliation(s)
- V Becette
- Department de Pathologie, INSERM E0017, Centre René Huguenin, Saint-Cloud, France.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Karayan-Tapon L, Menet E, Guilhot J, Levillain P, Larsen CJ, Kraimps JL. Topoisomerase II alpha and telomerase expression in papillary thyroid carcinomas. Eur J Surg Oncol 2004; 30:73-9. [PMID: 14736527 DOI: 10.1016/j.ejso.2003.10.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND Altered topoisomerase II alpha (Topo II alpha) expression and telomerase activity (TA) reflect tumour cell growth and malignant transformation. METHODS We examined TA by using a TRAP assay and expression of Topo II alpha by immunohistochemical analysis in a series of 27 cases of papillary thyroid carcinoma (PTC). RESULTS Topo II alpha labelling index (LI) ranged from 0.1 to 4.2% and was significantly associated with patient age (r=-0.42, p=0.003), with higher levels of Topo II alpha in patients under 40 years. There was no relationship between Topo II alpha LI, AGES score or other clinical outcome. TA was detected in 14 PTC, with relative levels ranging from 1.2 to 102 units. A significant positive correlation between the multiplicity of tumoral foci and the TA levels (p<10(-2)) was noted. CONCLUSION We concluded that Topo II alpha cannot be used as a marker of tumour aggressiveness. Furthermore, enhanced Topo II alpha expression in PTCs from patients less than 40 years old suggests that this age group might benefit from Topo II inhibitor chemotherapy.
Collapse
Affiliation(s)
- L Karayan-Tapon
- Laboratoire de Protéines et Inflammation, CHU la Milétrie, 86021 Poitiers Cedex, France
| | | | | | | | | | | |
Collapse
|
21
|
Becette V, Chérel P, Menet E, Yacoub S, Brain E, Hagay C, Guinebretière JM. [Biopsy of breast microcalcifications using an 11-Gauge vacuum-assisted device: roles and challenges for the pathologist]. Ann Pathol 2003; 23:496-507. [PMID: 15094588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
Stereotactic 11-Gauge vacuum-assisted biopsy provides a valuable tool in the diagnosis of mammographically detected breast microcalcifications. However, this new diagnostic technology presents some limitations and requires a close collaboration between radiologists, pathologists and physicians. The aim of this work is to propose a practical approach in the management of large core biopsies and to summarize the different difficulties faced by the pathologist in the management and histological interpretation of specimens issuing from this device.
Collapse
|
22
|
Jayle C, Corbi P, Eugene M, Carretier M, Hebrard W, Menet E, Hauet T. Beneficial effect of polyethylene glycol in lung preservation: early evaluation by proton nuclear magnetic resonance spectroscopy. Ann Thorac Surg 2003; 76:896-902. [PMID: 12963225 DOI: 10.1016/s0003-4975(03)00662-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Proton nuclear magnetic resonance spectroscopy can be used to measure organic molecules in biological fluids. In this study, proton nuclear magnetic resonance spectroscopy of bronchoalveolar lavage was assessed to detect cellular damage in lung transplants. Also we evaluated a polyethylene glycol solution in lung preservation. METHODS An isolated perfused and working pig lung was used to assess initial pulmonary function after in situ cold flush and cold storage for 6 hours in three preservation solutions: (1) Euro-Collins solution, (2) University of Wisconsin solution, and (3) low potassium solution with polyethylene glycol (PEG). Pulmonary vascular resistance and partial pressure of arterial oxygen were measured during reperfusion. Bronchoalveolar lavage was studied by proton nuclear magnetic resonance spectroscopy and a histologic study of the lungs was done at the harvest after ischemia and after reperfusion. RESULTS Partial pressure of arterial oxygen and pulmonary vascular resistance were significantly better in PEG compared with Euro-Collins solution (p = 0.011). Interstitial edema was significantly higher in Euro-Collins solution (2.4 +/- 0.24; p = 0.02) and University of Wisconsin solution (2.7 +/- 0.20; p = 0.0003) than PEG (2 +/- 0.16). Mitochondria scale was better in PEG (8.1 +/- 0.46) than in Euro-Collins solution (6.2 +/- 0.37; p = 0.0001) or University of Wisconsin solution (5.6 +/- 1.36; p = 0.0046). In bronchoalveolar lavage proton nuclear magnetic resonance spectroscopy spectra, lactate, pyruvate, citrate, and acetate were only detected after reperfusion, with a significantly reduced production of acetate in PEG. Pyruvate was reduced at the limit of significance in PEG versus University of Wisconsin solution. CONCLUSIONS Proton nuclear magnetic resonance spectroscopy seems to be a simple and suitable method for assessment of early injury to the lung transplant. In this experimental study, PEG preserved the lung better than University of Wisconsin solution and Euro-Collins solution in both the proton nuclear magnetic resonance spectroscopy study as well as the physiologic study.
Collapse
|
23
|
Ancey C, Menet E, Corbi P, Fredj S, Garcia M, Rücker-Martin C, Bescond J, Morel F, Wijdenes J, Lecron JC, Potreau D. Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation. Cardiovasc Res 2003; 59:78-85. [PMID: 12829178 DOI: 10.1016/s0008-6363(03)00346-8] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
OBJECTIVES Recent in vivo and in vitro studies in animals have demonstrated that cytokines of the IL-6 family are involved in cardiac hypertrophy and in protection of cardiomyocytes against apoptosis. The present study aims to analyse the capacity of human atrial cardiac cells (i.e., cardiomyocytes and fibroblasts) to display the gp130 receptor subunit, and to evaluate its functionality. METHODS Twenty human atrial biopsies were used for immunohistochemistry, in situ hybridisation, and western blot analysis or dissociated for isolation and primary culture of cardiac cells. RESULTS Fibroblasts present in tissue or maintained in primary culture clearly express gp130 whereas the signal in cardiomyocytes is weaker. Culture of cardiac cells with a gp130 agonist antibody enhances atrial natriuretic peptide (ANP), beta myosin heavy chain (beta-MHC) expression in cardiomyocytes, and significantly increases the cell surface area microm(2)). This process could involve STAT3 (signal transducer and activator of transcription 3) phosphorylation. CONCLUSIONS These results demonstrate that gp130 activation in human cardiac cells leads to cardiomyocyte hypertrophy. We discuss several hypotheses on the role of IL-6-type cytokines on cardiomyocyte functions.
Collapse
MESH Headings
- Aged
- Analysis of Variance
- Antibodies, Blocking/pharmacology
- Antigens, CD/immunology
- Antigens, CD/metabolism
- Antigens, CD/pharmacology
- AraC Transcription Factor
- Atrial Natriuretic Factor/analysis
- Bacterial Proteins
- Blotting, Western/methods
- Cardiomegaly/metabolism
- Cardiomegaly/pathology
- Cell Size
- Cells, Cultured
- Cytokine Receptor gp130
- DNA-Binding Proteins/analysis
- Fibroblasts/metabolism
- Fluorescent Antibody Technique, Indirect
- Heart Atria
- Humans
- Immunohistochemistry/methods
- In Situ Hybridization/methods
- Interleukin-6/immunology
- Interleukin-6/metabolism
- Membrane Glycoproteins/immunology
- Membrane Glycoproteins/metabolism
- Membrane Glycoproteins/pharmacology
- Middle Aged
- Myocytes, Cardiac/metabolism
- Myocytes, Cardiac/pathology
- Myosin Heavy Chains/analysis
- Phosphorylation
- Quaternary Ammonium Compounds/pharmacology
- Receptors, Cytokine/analysis
- Receptors, Cytokine/genetics
- Receptors, Cytokine/immunology
- Receptors, Interleukin-6/metabolism
- Repressor Proteins/pharmacology
- STAT3 Transcription Factor
- Trans-Activators/analysis
- Transcription Factors
Collapse
Affiliation(s)
- Cecile Ancey
- Laboratoire des Biomembranes et Signalisation Cellulaire, UMR CNRS 6558, Université de Poitiers, 40 avenue du recteur Pineau, 86022 Poitiers Cedex, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
Most of the TSH effects on the proliferation and differentiation of thyroid cells are mediated by cAMP via an adenylyl cyclase-activating Gs protein. TSH receptor responsiveness in cell cultures, is regulated by G protein-coupled receptor kinase (GRK) 2 and 5. To determine whether an alteration in activity and expression of GRKs might be associated with variable levels of TSH receptor desensitization in vivo, we studied human thyroid tissues including 21 normal tissues and 18 differentiated carcinomas. GRK activity was assayed by rhodopsin phosphorylation, and GRK protein and mRNA expressions assessed by immunoblotting and real-time quantitative RT-PCR, respectively. GRK2 and GRK5 were found as the predominant isoforms in the human thyroid. GRK5 protein expression was significantly decreased in differentiated thyroid carcinoma (P < 0.02) and paralleled a decrease in GRK mRNA expression (P < 0.02). In contrast, no difference in protein and mRNA levels of GRK2 were observed between normal and cancerous thyroid tissues. Although GRK2 protein levels correlated with GRK activities, we demonstrated a significant increase in GRK activity in differentiated thyroid carcinoma (P < 0.02). Less TSH receptor desensitization occurred in differentiated carcinoma than in normal thyroid tissue, as judged by TSH-stimulated cAMP response in human thyroid cells in primary culture. In conclusion, this study indicates that GRK2 activity and GRK5 expression have opposite regulations in cancer cells. Furthermore, the decrease in GRK5 expression may underlie the reduction in homologous desensitization of the TSH receptor in differentiated thyroid carcinoma, contributing to explain the increased cAMP levels in these tumors.
Collapse
Affiliation(s)
- Thierry Métayé
- Biophysics Laboratory, Department of Pathology, Jean Bernard Hospital, BP 577, 86021 Poitiers Cedex, France.
| | | | | | | |
Collapse
|
25
|
Jayle C, Hauet T, Menet E, Hébrard W, Hameury F, Eugene M, Carretier M, Corbi P. Beneficial effects of polyethylene glycol combined with low-potassium solution against lung ischemia/reperfusion injury in an isolated, perfused, functional pig lung. Transplant Proc 2002; 34:834-5. [PMID: 12034200 DOI: 10.1016/s0041-1345(01)02927-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- C Jayle
- Laboratoire de Transplantation Experimentale, INRA Le Magneraud, Surgères, France
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
The iliac venous leimyosarcoma is rare, usually malignant, and often occurs with oedema or phlebitis. We report one case of iliac venous leiomyosarcoma revealed by cruralgia. A 69 years old patient, presented with a left cruralgia which had been developing for three months and which happened after an insignificant trauma. The clinical examination objectified a stiff painful mass of the left iliac fossa together with left psoitis. The initial pelvic tomodensitometry showed a mass at the contact of the psoas muscle. At first, the diagnosis of a psoas haematoma complicated by a compressive cruralgia was evocated. Two months ago, the patient had a pulmonary embolism. At his hospitalisation, considering the persistent cruralgia, a tomodensitometry and a pelvic magnetic resonance imaging were carried out and had shown an heterogeneous mass that was including the iliac vessels. The result of the anatomopathologic examination was leiomysarcoma. Due to the disease's evolution (pulmonary metastasis), only a medical treatment by chemotherapy was undertaken and the patient died a few weeks later. The association of phlebitis and cruralgia should let us think of the diagnosis of vascular neoplasm. Indeed, only an early diagnosis enables a curative treatment.
Collapse
Affiliation(s)
- C Camiade
- Service de chirurgie vasculaire, CHU la Milétrie, 86021 Poitiers, France.
| | | | | | | | | |
Collapse
|
27
|
Torremocha F, Hadjadj S, Menet E, Kas A, Bourgeois H, Levillain P, Bataille B, Maréchaud R. [Pituitary germinoma presenting as a pseudotumoral lymphocytic hypophysitis in a man]. Ann Endocrinol (Paris) 2002; 63:13-7. [PMID: 11937977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
A 45-year-old man presented with headaches and extraocular muscle palsy due to a sellar mass extending into the right cavernous sinus. Hormonal determinations revealed a gonadotrophic insufficiency. A transsphenoidal surgical removal revealed a lymphocytic hypophysitis with fibrosis and necrosis. Rapid growth of the pseudotumor was noted despite a high dose steroid therapy (1 mg/kg/d) for a month. Further biological and histopathological investigations were performed. They showed a high cerebrospinal fluid (CSF) B-human chorionic gonadotropin (ss-HCG) level of 12 UI/L (normal<5 UI/L), normal plasma BHCG level, and undetectable CSF and plasma alpha-fetoprotein levels. The tumors cells showed a positive reactivity for placental alkaline phosphatase and for vimentin. These findings were consistent with an inflammatory lymphocytic process caused by an intrasellar germinoma. Chemotherapy was ill-tolerated and external radiotherapy was ineffective.
Collapse
Affiliation(s)
- F Torremocha
- Services de Médecine Interne, Endocrinologie et Maladies Métaboliques, France
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Menet E, Corbi P, Ancey C, Morel F, Delwail A, Garcia M, Osta AM, Wijdenes J, Potreau D, Lecron JC. Interleukine-6 (IL-6) synthesis and gp130 expression by human pericardium. Eur Cytokine Netw 2001; 12:639-46. [PMID: 11781191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Growing evidence shows that cytokines of the IL-6 family play an important regulatory role in heart physiology such as inducing cardiomyocyte hypertrophy. The purpose of this study was to see if IL-6 and its soluble receptors (sIL-6R and sgp130) could be detected in pericardial fluids, and to see if they are produced by the pericardium. We report that human pericardial fluid from patients with coronary pathologies contained IL-6, sIL-6R, and sgp130. However, the levels present in sera and pericardial fluid did not correlate, which suggests local production. This observation was confirmed by in vitro studies demonstrating massive IL-6 production by cultured pericardial samples, which could be strongly inhibited by methylprednisolone. RT-PCR studies revealed that IL-6 was weakly expressed in fresh tissues and strongly induced after culture. In situ hybridisation and immunohistochemical analysis showed that IL-6 and gp130 were mainly present in mesothelial cells. sIL-6R and sgp130 were also produced by pericardium in vitro, and their synthesis was upregulated by methylprednisolone. Taken together, these results demonstrate that IL-6 is present in pericardial fluid and that its presence could be due to synthesis by pericardial tissue. In vitro studies suggest that IL-6 production by this tissue could be strongly induced and regulated. A potential paracrine role of these factors in cardiomyocyte functions in normal or pathological conditions is discussed.
Collapse
Affiliation(s)
- E Menet
- Laboratoire d'Anatomie de Cytologie Pathologiques, Centre Hospitalier Universitaire, Poitiers, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Menet E, Petit ML, Bridoux F, Touchard G, Duport G, Levillain P, Babin P. [Mixed type amyloidomas, beta2 microglobulin and AL lambda, in a long term hemodialysis patient]. Nephrologie 2001; 22:115-8. [PMID: 11436666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
A frequent complication of hemodialysis is deposition of beta 2-microglobulin amyloid in tendons and joints. Soft tissues involvement is exceptional. A 74 year-old woman on hemodialysis for 21 years developed two bilateral and symmetric tumours in gluteal regions causing discomfort when sitting. Histology, immunohistochemistry and electron microscopy showed that deposit consisted of predominant beta 2-microglobulin and lambda light chain. This is an unusual localisation of amyloidosis developing late in the course of hemodialysis. It may be perhaps initiated by chronic traumatism and be promoted by the light chain lambda of immunoglobulin.
Collapse
Affiliation(s)
- E Menet
- Service d'anatomie et de cytologie pathologiques, Hôpital Jean Bernard, Poitiers.
| | | | | | | | | | | | | |
Collapse
|
30
|
Menet E, Vabres P, Brecheteau P, Bonneau-Herve F, Duport G, Levillain P, Larregue M, Babin P. [Pigmented Paget's disease of the male nipple]. Ann Dermatol Venereol 2001; 128:649-52. [PMID: 11427802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
BACKGROUND Mammary Paget's disease unfrequently occurs in males, and may be pigmented in rare instances. Differential diagnosis with malignant melanoma relies on immunohistochemical studies. CASE REPORT A case of Paget's disease of the nipple in a 76 year-old male is reported, clinically mimicking a malignant melanoma because of massive pigmentation. Histologically, large Paget's clear cells were intermingled with numerous melanin-rich dendritic melanocytes. An underlying ductal carcinoma was found. After differential immunohistochemical staining, diagnosis of Paget's disease could be unequivocally substantiated since Paget's cells stained for epithelial markers, c-erbB-2 and hormonal receptors, whereas protein S100 and HMB45 were negative. DISCUSSION Pigmentation in mammary Paget's disease occurs preferentially in males. Pigmentation results from numerous melanocytes with abundant melanin in close contact with Paget's cells. An increased number of melanocytes may also be observed in cutaneous metastatic breast carcinomas. It could result from a chemotactic factor produced by neoplastic cells.
Collapse
MESH Headings
- Aged
- Antigens, Neoplasm
- Biomarkers, Tumor/blood
- Breast Neoplasms, Male/blood
- Breast Neoplasms, Male/immunology
- Breast Neoplasms, Male/pathology
- Diagnosis, Differential
- Genes, erbB-2/physiology
- Humans
- Immunohistochemistry
- Keratins/blood
- Male
- Melanoma/blood
- Melanoma/immunology
- Melanoma/pathology
- Melanoma-Specific Antigens
- Neoplasm Proteins/blood
- Nipples
- Paget's Disease, Mammary/blood
- Paget's Disease, Mammary/immunology
- Paget's Disease, Mammary/pathology
- S100 Proteins/blood
- Skin Neoplasms/blood
- Skin Neoplasms/immunology
- Skin Neoplasms/pathology
Collapse
Affiliation(s)
- E Menet
- Service d'Anatomie et de Cytologie Pathologiques, Centre Hospitalier Universitaire, Poitiers
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Menet E, Kraimps JL, Guillard O, Levillain P, Babin P. [A needle can hide a lot of things]. Ann Pathol 2000; 20:269-70. [PMID: 10891730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Affiliation(s)
- E Menet
- Service d'Anatomie et de Cytologie Pathologiques, Hôpital Jean Bernard, Poitiers
| | | | | | | | | |
Collapse
|
32
|
Abstract
OBJECT The authors present a retrospective analysis of 248 immunocompetent patients with primary intracerebral lymphoma treated at 19 French and Belgian medical centers between January 1980 and December 1995. METHODS This study involved 127 female and 121 male patients with a median age of 61 years (range 2-88 years). All tumors available for review were classic diffuse non-Hodgkin's lymphoma, for which the phenotype was determined in 220 patients: 212 (96.4%) were B-cell and eight (3.6%) were T-cell type tumors. According to the Revised European-American classification of lymphoid neoplasms, most lesions were diffuse large cell tumors (62%). A total of 196 tumors were reviewed in 127 patients for whom preoperative computerized tomography and magnetic resonance studies were available. There was a single lesion in 66% of the cases, with a supratentorial location in 87%. Tumor location in the basal ganglia, corpus callosum, or fornix, infiltration of the periventricular ependyma, or a mirror pattern, were strongly suggestive of a lesion of lymphomatous origin. The histological diagnosis was obtained after surgical resection in 116 patients, with the remainder undergoing biopsy sampling only. Of the 248 patients studied, 129 (52%) received chemotherapy plus radiation therapy, 60 (24%) received radiation therapy alone, 35 (14%) received chemotherapy alone, and 24 (10%) received no postsurgical treatment. CONCLUSIONS Using univariate analysis, the authors determined prognostic factors that were significantly associated with a favorable impact on survival including age younger than 60 years, radiation therapy (without evidence of a dose-response relationship), radiation therapy combined with chemotherapy, and chemotherapy consisting of anthracycline. Partial surgical resection was an unfavorable prognostic factor. Multivariate analysis was used to confirm the independent prognostic value of radiation therapy, age, chemotherapy consisting of anthracyclines or methotrexate, and partial surgical resection. This European survey provides a reasonable basis for the treatment of primary intracerebral lymphoma with the following sequence: stereotactic biopsy sampling, chemotherapy with a methotrexate- and anthracycline-based regimen, followed by cranial irradiation.
Collapse
Affiliation(s)
- B Bataille
- Department of Neurological Surgery, Radiation Oncology, Radiology, and Pathology, University of Poitiers Medical School, France.
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Kraimps JL, Canzian F, Jost C, Menet E, Amati P, Levillian P, Harach R, Lesueur F, Barbier J, Romeo G, Bonneau D. Mapping of a gene predisposing to familial thyroid tumors with cell oxyphilia to chromosome 19 and exclusion of JUN B as a candidate gene. Surgery 1999; 126:1188-94. [PMID: 10598206 DOI: 10.1067/msy.2099.102606] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
BACKGROUND Familial nonmedullary thyroid carcinoma (FNMTC) is a clinical entity characterized by a more aggressive phenotype than the sporadic counterpart. The transmission of susceptibility of FNMTC is compatible with autosomal dominant inheritance. We report the identification of a new entity of FNMTC and the mapping of the responsible gene named TCO (for thyroid tumor with cell oxyphilia). METHODS In one family, multinodular goiters were diagnosed in six individuals and papillary thyroid carcinoma was diagnosed in three. Eight patients were operated on. Blood samples were collected from the nine affected patients and from eight unaffected relatives. The gene was mapped by linkage analysis with a whole-genome panel of microsatellite markers. RESULTS The neoplastic cells from all lesions showed characteristic faint to marked cytoplasmic oxyphilia. We found a logarithm of odd ratio (LOD) score of 2.41 at theta = 0 for marker D19S586. Additional markers were typed in the region and were found to be in linkage, with LOD scores peaking at markers D19S916 (Zmax = 3.01 at theta = 0) and D19S413 (Zmax = 2.95 at theta = 0). All these markers have been physically mapped to 19p13.2. CONCLUSIONS TCO was mapped to chromosome 19p13.2. Interestingly, both the benign and malignant thyroid tumors in this family exhibit some degree of oxyphilia, which has not been described until now in the familial forms of NMTC.
Collapse
Affiliation(s)
- J L Kraimps
- Department of Endocrine Surgery, Jean Bernard Hospital, Poiters, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Menet E, Wager I, Babin M, Magnin G, Babin P. [Multiple vulvar cystic and papillary fibroadenomas]. J Gynecol Obstet Biol Reprod (Paris) 1999; 28:830-2. [PMID: 10635487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
We report a new case of multiple vulvar fibroadenoma arising in a 47-year-old woman. This papillary and cystic lesion shares similarities with papilliferum hidradenoma and mammary fibroadenomas. After describing clinical and pathological characteristics, we try to detail its origin according to the literature and particularly its relationship with anogenital sweat glands and ectopic mammary glands.
Collapse
Affiliation(s)
- E Menet
- Service d'Anatomie et de Cytologie Pathologiques, Hôpital Jean Bernard, Poitiers
| | | | | | | | | |
Collapse
|
35
|
Abstract
This paper describes the pathology of thyroid tumours showing an autosomal mode of inheritance linked to a gene that maps to chromosome 19p13.2. All the affected members from the family (seven males and two females; mean age 23 years) were clinically euthyroid and presented with nodular goitre; tumour recurrence after thyroidectomy was observed in four. In four of the five patients studied, the tumours were multifocal, bilateral well demarcated or encapsulated and composed of follicles, papillae, trabeculae/solid areas (often resembling hyalinizing trabecular adenoma of the thyroid) or an admixture, formed by cells with pale to intense cytoplasmic eosinophilia. A diagnosis of multiple adenomatous goitre was made in the thyroidectomy specimen from two patients, while the other two patients showed, in addition to multiple adenomas, a co-existent oxyphil papillary carcinoma. The fifth patient had an oxyphil cell carcinoma. All tumours were of follicular cell origin as shown by immunocytochemistry. Less than a third of the benign tumours and all three carcinomas showed a variable number of neoplastic cells diffusely immunostained for mitochondria. Histological findings of a 'multiple adenomatous goitre', non-endemic 'multinodular goitre' or multiple neoplasms of follicular cell origin with the morphology of those described here, particularly in young patients, should alert the pathologist and physician to the possibility of an inherited trait, with its implications for family screening. The tumours are usually benign and well demarcated but because of multicentricity and consequently increased risk of recurrence and/or progression to carcinoma, total thyroidectomy should be advocated.
Collapse
Affiliation(s)
- H R Harach
- Department of Histopathology and Morbid Anatomy, Royal London Hospital, London, U.K
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Menet E, Etchandy-Laclau K, Corbi P, Levillain P, Babin P. [Alveolar adenoma: a rare peripheral pulmonary tumor]. Ann Pathol 1999; 19:325-8. [PMID: 10544770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
Alveolar adenoma was first described in 1986. It is a benign peripheral lung neoplasm present more frequently in middle-aged woman. We report a new case occurring in 52 year-old woman. We describe histopathological and immunohistochemical characteristics. Then, this observation is compared with the 11 cases previously published. Finally, we try to understand its origin.
Collapse
Affiliation(s)
- E Menet
- Service d'Anatomie et de Cytologie Pathologiques, Hôpital Jean-Bernard, Poitiers
| | | | | | | | | |
Collapse
|
37
|
Goujon JM, Hauet T, Menet E, Levillain P, Babin P, Carretier M. Histological evaluation of proximal tubule cell injury in isolated perfused pig kidneys exposed to cold ischemia. J Surg Res 1999; 82:228-33. [PMID: 10090834 DOI: 10.1006/jsre.1998.5526] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
BACKGROUND Ischemic injury of the renal allograft before transplantation is a major cause of impaired graft function. Proton nuclear spectroscopy provides a useful technique for evaluating proximal tubular activity. In addition to this technique, we proposed a histological grading system for quantifying proximal tubule alterations. METHODS The aim of this study was to evaluate the histological lesions of tubule epithelial cells in the model of isolated perfused pig kidneys following 48 to 72 h of cold storage in Euro-Collins solution. Normothermic isolated perfused pig kidneys were randomized in three experimental groups : Group 1, control group; cold flush with cold heparinized solution followed by immediate reperfusion (n = 6); Group 2, 48 h of cold storage in Euro-Collins followed by reperfusion (n = 6); Group 3, 72 h of cold storage in Euro-Collins followed by reperfusion (n = 6). Proton nuclear spectroscopy of urine and biochemical studies were performed for whole renal functional evaluation during reperfusion. Optical and electron microscopy analyses of the reperfused kidneys were performed by four investigators and the degree of cell injury was assessed using 8 different criteria in a 5-scale numerical score. RESULTS Numerical scores corroborate the results from NMR spectroscopy and differed significantly between the three groups studied. The degree of proximal tubule cell damage was increased with prolonged cold ischemia as shown particularly in Group 3. CONCLUSION The results from this study showed that analysis of cell injury based on an histological grading system in the model of isolated perfused kidney allows the quantification of the degree of proximal tubule injury. Thus, such morphological system analysis could be a useful method for quantifying tubule cell injuries observed under various physiopathological conditions.
Collapse
Affiliation(s)
- J M Goujon
- Service d'Anatomo-Pathologie - Unité de Microscopie Electronique, Centre Hospitalier Universitaire, La Milétrie, Poitiers, France
| | | | | | | | | | | |
Collapse
|
38
|
Menet E, Goujon JM, Levillain P, Babin P. [Pathological anatomy of primary cerebral lymphoma]. Neurochirurgie 1998; 43:357-60. [PMID: 9706612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
In this retrospective study (1986-1996), a series of 250 immunocompetent patients (SFNC series) with primary malignant lymphoma of the central nervous system is reviewed and the lymphomas redefined using the REAL (Revised European-American classification of Lymphoid neoplasms) and the modified Kiel classifications. All the tumors available for review were classic diffuse non-Hodgkin's lymphomas. Thirty-eight were unclassifiable due to small size and artifacts in the specimens. Eight cases were of T-cell type (3.7%). The 212 others cases were B-cell type. According to the REAL classification, the high majority was diffuse large cell (62%). Following the modified Kiel classification percentage of cases categorized as low and high grade of malignancy were 22.4% and 77.6% respectively.
Collapse
Affiliation(s)
- E Menet
- Laboratoire d'Anatomopathologie, CHU, Poitiers
| | | | | | | |
Collapse
|
39
|
Donal E, Coisne D, Corbi P, Christiaens L, Menet E, Allal J, Barraine R. [Cardiac lymphoma disclosed by tamponade and complete atrioventricular block: apropos of a surgically treated case. Heart and lymphoma]. Ann Cardiol Angeiol (Paris) 1997; 46:667-70. [PMID: 9587432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Cardiac lymphoma is becoming increasingly frequent, especially in the context of acquired immune deficiency syndrome, and due to progress in imaging, particularly echocardiography. The authors report the case of a 49-year-old patient in whom the diagnosis of cardiac lymphoma was established in the presence of complete atrioventricular block, tamponade and right atrial tumour. The authors review the various electrocardiographic and echocardiographic features of cardiac lymphoma.
Collapse
Affiliation(s)
- E Donal
- Service de Cardiologie A, CHU Poitiers, Hôpital La Milétrie
| | | | | | | | | | | | | |
Collapse
|
40
|
Goujon JM, Bataille B, Menet E, Lapierre F. [Neurinomas-neurofibromas]. Neurochirurgie 1997; 43:35-8. [PMID: 9205625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Among primary nerve sheath tumors, schwannomas and neurinomas are the most common. While the schwannomas (neurilemomas) originate in schwann cells, neurofibromas arise from all the constitutive parts of the nerve. The behavior of each tumor is quite different and only neurofibromas may present malignant transformation, especially when arising in patients with Von Recklinghausen disease (NF1 with multiple neurofibromas).
Collapse
Affiliation(s)
- J M Goujon
- Service d'Anatomie Pathologique, CHU, Poitiers
| | | | | | | |
Collapse
|
41
|
Roblot F, Roblot P, Menet E, Lelièvre E, Gombert J, Lecron J. Clonage de lymphocytes T infiltrant l'artère temporale et circulant au cours de la maladie de Horton. Rev Med Interne 1996. [DOI: 10.1016/s0248-8663(97)80948-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|